NECTIN4 heterogeneity and molecular diversity in bladder cancers: Deconstructing the activity of an antibody-drug conjugate Editorial

  


Authors: Teo, M. Y.; Rosenberg, J. E.
Title: NECTIN4 heterogeneity and molecular diversity in bladder cancers: Deconstructing the activity of an antibody-drug conjugate
Abstract: Nectin-4 is the target for enfortumab vedotin, a novel antibody–drug conjugate. NECTIN4 gene expression differs considerably across different molecular subtypes and is shown to be important for enfortumab vedotin efficacy. See related article by Chu et al., p. 5123 Ó2021 American Association for Cancer Research
Journal Title: Clinical Cancer Research
Volume: 27
Issue: 18
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2021-09-15
Start Page: 4950
End Page: 4952
Language: English
DOI: 10.1158/1078-0432.Ccr-21-1807
PUBMED: 34281911
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115006968&doi=10.1158%2f1078-0432.CCR-21-1807&partnerID=40&md5=8b0d5b54d1b20846c70bc4aeff6576e3
Notes: Article -- Export Date: 1 October 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jonathan Eric Rosenberg
    510 Rosenberg
  2. Min Yuen Teo
    104 Teo
Related MSK Work